Semaglutide vs Tirzepatide: Weight Loss, Lean Mass, and Which GLP-1 Works Best

The internet wants this to be simple. Zepbound beats Wegovy.

For weight loss alone, the newer head-to-head data does point that direction. In the 2025 SURMOUNT-5 trial, tirzepatide produced more weight loss than semaglutide at 72 weeks in adults with obesity but without diabetes.

But that is not the whole clinical decision.

I care about the scale. I also care about cardiovascular history, sleep apnea, gallbladder risk, diabetes medications, pregnancy plans, lean mass, nausea, constipation, cost, access, and whether the patient is losing muscle faster than they are rebuilding a life.

The Fast Answer

• Tirzepatide produced greater average weight loss than semaglutide in the 2025 SURMOUNT-5 head-to-head trial, about 20.2% vs 13.7% at 72 weeks.
• Semaglutide has a specific FDA cardiovascular risk-reduction indication for adults with established cardiovascular disease and overweight or obesity.
• Tirzepatide has an FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
• Both can cause GI side effects and both require careful monitoring for pancreatitis symptoms, gallbladder symptoms, dehydration, kidney injury risk, hypoglycemia risk with diabetes medications, and nutrition status.
• The best choice is not just "which one loses more weight." It is which one fits the patient's risk profile and can be sustained safely.

The Clean Comparison

Clinical Question	Semaglutide	Tirzepatide
Common obesity brand	Wegovy	Zepbound
Mechanism	GLP-1 receptor agonist	GIP + GLP-1 receptor agonist
Weight-loss signal	Strong	Stronger in head-to-head obesity data
Cardiovascular indication	Yes, for adults with established CVD and overweight/obesity	Not the same FDA CV risk-reduction indication as Wegovy
Sleep apnea indication	No specific OSA indication	Yes, moderate-to-severe OSA in adults with obesity
Common side effects	nausea, vomiting, diarrhea, constipation, abdominal pain	nausea, diarrhea, vomiting, constipation, abdominal pain, reflux, fatigue
Clinical focus	CV history may matter more	Weight-loss magnitude or OSA may matter more

This is why I do not choose these medications from a TikTok comparison chart.

What The 2025 Head-To-Head Trial Changed

Before 2025, clinicians were comparing separate trial programs: STEP for semaglutide, SURMOUNT for tirzepatide. Helpful, but imperfect.

SURMOUNT-5 gave us a direct comparison. Adults with obesity but without type 2 diabetes were randomized to tirzepatide or semaglutide and treated for 72 weeks. Tirzepatide produced greater average weight loss and waist circumference reduction.

The useful takeaway is blunt.

Tirzepatide is usually the stronger weight-loss tool. That does not automatically make it the right tool.

Medication choice still has to survive insurance coverage, dose tolerance, constipation, nausea, food intake, protein intake, resistance training, diabetes medications, surgical plans, and whether the patient can follow up.

Cardiovascular History Changes The Conversation

Wegovy has an FDA-approved cardiovascular risk-reduction indication for adults with established cardiovascular disease and overweight or obesity. That approval came after SELECT, a large cardiovascular outcomes trial in adults without diabetes.

That matters.

If a patient has prior cardiovascular disease, I do not treat GLP-1 selection as a beauty contest between before-and-after photos. I want the actual cardiometabolic record.

• prior heart attack, stroke, peripheral artery disease, or revascularization history
• blood pressure and lipid treatment
• diabetes or prediabetes status
• kidney function
• family history
• current cardiology plan

The goal is not only weight loss. It is risk reduction.

Sleep Apnea Changes The Conversation Too

Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, used with reduced-calorie diet and increased physical activity.

That does not mean it replaces sleep evaluation. It means sleep apnea should not be ignored when choosing a weight-management strategy.

If someone snores, wakes up gasping, has morning headaches, daytime sleepiness, resistant hypertension, or ADHD-like brain fog, I want sleep apnea assessed. Untreated sleep apnea can make mood, focus, appetite, blood pressure, and fatigue look like separate problems.

They may not be separate.

Lean Mass Is Where People Get Sloppy

Losing weight is not the same as improving body composition.

With GLP-1 and GIP/GLP-1 medications, some weight loss will be lean mass. That is expected with major weight reduction, but it still matters clinically.

I want the plan to cover the basics patients are usually not given.

• protein intake
• resistance training
• sleep
• constipation prevention
• hydration
• micronutrient risk if intake drops sharply
• functional markers, not just the scale

If a patient is losing weight but also losing strength, hair, energy, and the ability to eat enough protein, I do not call that a clean win.

When Semaglutide May Make More Sense

Semaglutide may be the stronger fit in several situations.

• established cardiovascular disease is central to the decision
• insurance covers Wegovy but not Zepbound
• the patient has tolerated semaglutide before
• slower weight loss feels clinically safer
• the prescriber wants to lean on the SELECT cardiovascular outcomes data

This is not a guarantee. It is a starting point.

When Tirzepatide May Make More Sense

Tirzepatide may be the stronger fit in a different pattern.

• the primary goal is greater weight reduction
• moderate-to-severe obstructive sleep apnea with obesity is part of the picture
• prior semaglutide response was inadequate or poorly tolerated
• insurance access is better
• the patient can follow a nutrition and strength plan during larger weight loss

Again, this is not automatic. The person in front of me matters more than the headline.

Safety Checks I Want Before And During Treatment

Before starting, I want the safety screen documented.

• pregnancy or pregnancy plans
• personal or family history of medullary thyroid carcinoma or MEN2
• pancreatitis history
• gallbladder disease
• kidney function and dehydration risk
• diabetes medications, especially insulin or sulfonylureas
• severe reflux, gastroparesis symptoms, or major GI disease
• prior bariatric surgery or restrictive eating patterns
• planned surgery or anesthesia
• mood changes or suicidal thoughts

During treatment, I watch for severe or persistent abdominal pain, repeated vomiting, dehydration, fainting, hypoglycemia symptoms, and rapid nutrition decline.

Those are not fine-print details. They are the clinical work.

My Read

If the only question is "which medication causes more weight loss," tirzepatide has the stronger current head-to-head data.

If the question is "which medication should this patient use," I need more information.

Bring the cardiovascular history. Bring the sleep history. Bring the medications. Bring the labs. Bring the reason prior attempts failed.

That is how GLP-1 care becomes medicine instead of a subscription.

San Francisco Optimization Note

For San Francisco patients already stacking GLP-1s with stimulants, supplements, hormones, sleep tracking, or longevity protocols, the next question is not just which medication causes more weight loss.

It is whether the whole pattern still makes clinical sense.

If appetite, sleep, anxiety, focus, alcohol use, nutrition, or medication tolerance changed after starting a GLP-1, diagnostic optimization in San Francisco is built to sort the psychiatric and medical signal before adding more interventions.

Considering GLP-1 Therapy?

A diagnostic weight-management visit should clarify whether medication is appropriate, which medication fits your risk profile, and what monitoring needs to happen before dose escalation.

At Horizon Peak Health, the discussion includes metabolic history, psychiatric medications, sleep, nutrition, side effects, and realistic maintenance planning.

Book a diagnostic consultation

Locations: Psychiatric evaluation in Rancho Palos Verdes, Psychiatric evaluation in Phoenix, Psychiatric evaluation in Chandler, and telehealth throughout California and Arizona.

---

References

• Aronne, L. J., Horn, D. B., le Roux, C. W., et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine.
• FDA. (2024). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight.
• FDA. (2024). FDA approves first medication for obstructive sleep apnea.
• DailyMed. WEGOVY prescribing information.
• DailyMed. ZEPBOUND prescribing information.
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine.

---

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. GLP-1 and GIP/GLP-1 medications are prescription treatments with specific indications, contraindications, and monitoring needs. Medication selection should be made with a qualified healthcare provider who can evaluate your medical history, pregnancy plans, diabetes medications, kidney function, gallbladder history, pancreatitis history, family or personal history of medullary thyroid carcinoma or MEN2, nutrition status, and lean-mass risk. Seek urgent medical care for severe or persistent abdominal pain, repeated vomiting, dehydration, fainting, signs of hypoglycemia, or another medical emergency. Do not start, stop, or change these medications without medical supervision.